Outlook Therapeutics said on Wednesday the U.S. health regulator has declined to approve its drug for a type of eye disease, ...

Outlook Therapeutics received notice that the Food and Drug Administration can't approve its biologics license application for a drug designed to treat macular degeneration.

A clinical trial is investigating whether a stem cell-derived patch can replace disease-damaged cells and restore vision. Age-related macular degeneration is a steadily worsening eye disease and the ...

Outlook Therapeutics shares slid after the company's macular degeneration drug was once again rejected by the Food and Drug Administration. The stock dropped 71% to 45 cents a share in after-hours ...

In July 2025, Novartis Pharmaceuticals conducted a study is to assess the effect of Iptacopan to prevent conversion of early ...

The PRIMA system is a subretinal implant designed to restore central vision in GA patients by replacing failed photoreceptors ...

The age-related macular degeneration (AMD) market in the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK ...

Age-related macular degeneration, the leading cause of vision loss and blindness for Americans 65 and older, is a progressive ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Please provide your email address to receive an email when new articles are posted on . The Foundation Fighting Blindness and the Nixon Visions Foundation are working together to launch the Nixon ...

Please provide your email address to receive an email when new articles are posted on . Researchers from the National Eye Institute found TIMP3 variants cause atypical presentations of Sorsby fundus ...

Retinal drusen are yellow/white-colored spots seen under the retina of your eye that are made up of proteins and a type of fat called lipids. The retina is the layer of cells lining the inside surface ...